Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Genscript Biotech (1548) Stock Price & Analysis

12 Followers

1548 Stock Chart & Stats

HK$30.38-HK$1.46(-4.59%)
At close: 4:00 PM GMT+8
HK$30HK$40HK$50Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 29.50 - HKD 32.34
52-Week Range
HKD 10.36 - HKD 49.46
Previous Close
HKD 31.84
Volume
N/A
Average Volume (3M)
45.22M
Market Cap
HKD 72.36B
Enterprise Value
HKD 22.93B
Total Cash (Recent Filing)
HKD 831.18M
Total Debt (Recent Filing)
HKD 254.68M
Price to Earnings (P/E)
―
Beta
1.33
Next Earnings
Mar 24, 2027 (Est.)
EPS Estimate
0.08
Last Dividend Ex-Date
Jun 05, 2017
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

LSG Growth And Margins

The Life Science Services segment combines strong growth with substantial operating margins, indicating meaningful scale benefits and customer demand. Management’s raised 25–30% growth guidance and margin targets suggest this segment can remain the group’s principal earnings and cash-generation engine over coming quarters.

AI-enabled Operating Advantage

AI-enabled validation, faster turnaround, and high processing throughput can improve customer value while supporting premium pricing and repeat demand. These capabilities also create operational scale advantages as AIDD activity expands, strengthening GenScript’s competitive position beyond simple capacity growth.

Manageable Leverage And Liquidity

Low leverage and a sizable cash position provide financial flexibility to fund planned capacity investment without relying on near-term equity issuance. This supports continued development of the company’s platforms and reduces balance-sheet pressure while operations and newer businesses scale.

Bears Say

Unstable Bottom-line Profitability

Despite improved revenue and operating margins, reported earnings remain highly volatile and are not yet consistently supported by core operations. The history of negative free cash flow also means recent cash improvement must be sustained before the company can demonstrate dependable earnings quality across business cycles.

ProBio Remains Unprofitable

ProBio is growing rapidly and improving operationally, but it still consumes earnings capacity while management works toward profitability. Reaching positive EBITDA depends on continued order growth, backlog conversion, and cost discipline, leaving execution risk in this strategically important development and manufacturing segment.

Bestzyme Profitability Pressure

Bestzyme’s modest growth alongside a wider operating loss shows that investment in the business is currently weighing on returns. Until product expansion and AI-enabled development translate into stronger scale economics, this segment may dilute consolidated profitability and require continued management attention.

Genscript Biotech News

1548 FAQ

What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$10.36 and its highest was HK$49.46 in the past 12 months.
What is Genscript Biotech’s market cap?
Genscript Biotech’s market cap is HK$72.36B.
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s next earnings report is estimated for Mar 24, 2027 (not yet confirmed), which is in 130 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Aug 17, 2026. The company reported -HK$0.463 earnings per share for the quarter, missing the consensus estimate of HK$0 by -HK$0.463.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Undervalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a dividend of HK$0.012 which represents an annual dividend yield of ―. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is 0.08.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,284,025,600 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -HK$0.463 in its last earnings report, missing expectations of HK$0. Following the earnings report the stock price went up 4.823%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in HK:1548
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology